Elevar Submits NDA for Lirafugratinib as Second-Line FGFR2-Driven Cholangiocarcinoma Therapy

  Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...

January 30, 2026 | Friday | News
Imviva Biotech’s CTD402 Granted FDA Orphan Drug Designation for Relapsed/Refractory T-ALL/LBL

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, announced that the U.S. Food and Drug ...

January 29, 2026 | Thursday | News
Longeveron Secures FDA Type C Meeting Ahead of Pivotal ELPIS II Data Readout in HLHS

ELPIS II top-line trial results are anticipated in the third quarter of 2026 Laromestrocel Biological License Application (BLA) submission for full tr...

January 28, 2026 | Wednesday | News
Gannet BioChem Acquires Laysan Bio to Expand Activated Polymer and Bioconjugation Capabilities

Gannet BioChem, a leading specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capit...

January 28, 2026 | Wednesday | News
Argo Biopharma and Novartis Dose First Patient in Phase 2b Trial of siRNA Therapy BW-20829

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, announ...

January 27, 2026 | Tuesday | News
HanchorBio and WuXi Biologics Enter Strategic Collaboration to Advance Next-Generation Fusion Proteins

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseas...

January 27, 2026 | Tuesday | News
Eisai and Biogen’s LEQEMBI IQLIK Moves Toward First At-Home Anti-Amyloid Treatment for Alzheimer’s

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing fo...

January 27, 2026 | Tuesday | News
Samsung Bioepis Releases First Quarter 2026 U.S. Biosimilar Market Report

Samsung Bioepis Co., Ltd. released its First Quarter 2026 Biosimilar Market Report, marking the twelfth edition of the Quarterly Biosimilar Market Report...

January 26, 2026 | Monday | Company results
ADLM Launches Data Science in Laboratory Medicine Certificate Program to Advance Data-Driven Care

The Association for Diagnostics & Laboratory Medicine (ADLM) announced the launch of its Data Science in Laboratory Medicine Certificate Program, des...

January 23, 2026 | Friday | News
Charles River Laboratories International And Gazi University Faculty of Medicine Advance Rare Disease Gene Therapy Through Strategic CDMO Collaboration

Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, announced a gene therapy contract developme...

January 22, 2026 | Thursday | News
LEO Pharma Initiates Phase 3 DELTA CARE 1 Trial of Delgocitinib Cream in Lichen Sclerosus

The phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitini...

January 22, 2026 | Thursday | News
Bayer and Vanderbilt University Medical Center Form Five-Year Strategic Collaboration to Advance Innovative Therapies

-Bayer and Vanderbilt University Medical Center (VUMC) announced that they have entered a strategic five-year collaboration agreement to advance innovati...

January 21, 2026 | Wednesday | News
Valneva Voluntarily Withdraws U.S. BLA and IND for Chikungunya Vaccine IXCHIQ® Following FDA Clinical Hold

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced that the Company has decided to voluntarily withdraw the biologics...

January 21, 2026 | Wednesday | News
Calitii, a Synechron Company, Secures ServiceNow Managed Services Contract With BridgeBio

Calitii, a Synechron company and global IT consultancy, announced it has secured a contract withBridgeBio, a biopharmaceutical company, to prov...

January 21, 2026 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close